Individualized recombinant human thrombomodulin (ART-123) administration in sepsis patients based on predicted phenotypes

Crit Care. 2019 Jun 24;23(1):231. doi: 10.1186/s13054-019-2521-7.

Authors

Daisuke Hasegawa¹, Osamu Nishida²

Affiliations

¹ Department of Anesthesiology and Critical Care Medicine, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
² Department of Anesthesiology and Critical Care Medicine, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan. nishida@fujita-hu.ac.jp.

No abstract available

Publication types

Letter

MeSH terms

Humans
Phenotype*
Precision Medicine / methods
Recombinant Proteins / genetics
Recombinant Proteins / therapeutic use
Sepsis / drug therapy*
Sepsis / genetics*
Sepsis / physiopathology
Thrombomodulin / genetics*
Thrombomodulin / therapeutic use

Substances

ART123
Recombinant Proteins
Thrombomodulin